Nobody wants to kick a dead horse but get the fork lift to move the R&D legacy out of the stable! Restructuring charges to be incurred will negatively affect their cash expenditures and actual results may differ materially from those originally anticipated. But, is saving R&D dollars by the retrenchment and switching tracks to let their telomerase inhibitor thoroughbred breakaway!
GERN closed at $1.117 and is down $0.02 to $1.12 on volume of only 36.1 K, so far … expect more attrition to this event as it settles around $1.10. SELL on news event, until it settles!